Scott Gottlieb Buys 200 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Scott Gottlieb purchased 200 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was bought at an average cost of $117.81 per share, with a total value of $23,562.00. Following the completion of the purchase, the director owned 12,723 shares of the company’s stock, valued at approximately $1,498,896.63. This represents a 1.60% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Illumina Stock Down 2.5%

Illumina stock traded down $2.94 during midday trading on Wednesday, reaching $116.38. The stock had a trading volume of 2,032,582 shares, compared to its average volume of 2,240,057. The company has a fifty day moving average price of $138.04 and a two-hundred day moving average price of $116.48. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $17.78 billion, a P/E ratio of 21.35, a PEG ratio of 2.24 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC purchased a new stake in Illumina during the fourth quarter valued at about $25,000. Board of the Pension Protection Fund bought a new stake in Illumina in the fourth quarter valued at $26,000. Creative Capital Management Investments LLC increased its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new position in Illumina in the 4th quarter worth $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the 4th quarter worth about $26,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ILMN. JPMorgan Chase & Co. cut their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Barclays upped their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Finally, Piper Sandler lowered their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $129.17.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.